Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (836)	2/20/1998 7:47:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

Attention News/Assignment/Business Editors: INFLAZYME PHARMACEUTICALS LTD. LIVE ON CANADA'S BUSINESS REPORT TORONTO, Feb. 20 / CNW - Inflazyme Pharmaceuticals Ltd. will be featured today on the Market in Profile segment of Canada's Business Report. President and Chief Executive Officer Dr. Hassan Salari is the invited guest. Canada's Business Report is the nation's leading radio business program heard on Talk 640 in Toronto (6:30 p.m.), CKGL 570 AM in Kitchener (6:30 p.m.), CKTB 610 AM in St. Catharines (6:30 p.m.), and CIQC 600 AM in Montreal (5:00 p.m.). The daily half-hour show is hosted by business journalist Ron Adams. Regular guests include Fred Ketchen of Scotia Capital Markets with detailed analysis of up-to-the-minute market activity, Paul Summerville of RBC Dominion Securities with a weekly economic analysis, and Canadian Federation of Independent Business CEO Catharine Swift reporting news affecting independent business. Market in Profile airs every Monday, Wednesday and Friday on Canada's Business Report. The five-minute segment provides interviews with senior executives from publicly traded companies across all industries within Canada. Market in Profile is available on streaming audio on the Canada NewsWire web site at www.newswire.ca.

To: David Culver who wrote (836)	2/24/1998 1:40:00 PM
From: Harold Lehman	Read Replies (2) \| Respond to of 1501

Dave, I did some calling around and found some info regarding the anticancer agents with which Inflazyme is joint venturing with Supergen (the agreement was signed last April). I spoke with Supergen's Executive Vice President, Dr. Raj Shrotrya, who was very enthusiastic about the potential of Inflazyme's compounds. He said that they were VERY interesting and said it with fervor. What has been going on is that IZP supplied Supergen with a small amount of a compound, which they tested. They needed more, which was given to them last week. Why the delay? The compound was originally produced by bacteria grown in an agar. It cannot be bulk produced by this method and required the development of a batch fermentative process in a liquid growth media (agar is solid for those who don't remember any biology). It took awhile to find an effective media and then produce much larger amounts. Inflazyme is now looking for a CRO to take over production, with the associated quality assurance. I am feeling fairly upbeat because it looks like there has been steady progress with a diverse stream of products. HL